- Home
- HQI vs CRVS Comparison
HQI vs CRVS Comparison
Compare HQI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- CRVS
- Stock Information
- Founded
- HQI 2002
- CRVS 2014
- Country
- HQI United States
- CRVS United States
- Employees
- HQI N/A
- CRVS N/A
- Industry
- HQI Professional Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- CRVS Health Care
- Exchange
- HQI Nasdaq
- CRVS Nasdaq
- Market Cap
- HQI 140.2M
- CRVS 459.0M
- IPO Year
- HQI N/A
- CRVS 2016
- Fundamental
- Price
- HQI $9.88
- CRVS $5.88
- Analyst Decision
- HQI Buy
- CRVS Strong Buy
- Analyst Count
- HQI 1
- CRVS 4
- Target Price
- HQI $13.00
- CRVS $15.00
- AVG Volume (30 Days)
- HQI 6.7K
- CRVS 565.6K
- Earning Date
- HQI 11-06-2025
- CRVS 11-11-2025
- Dividend Yield
- HQI 2.47%
- CRVS N/A
- EPS Growth
- HQI N/A
- CRVS N/A
- EPS
- HQI 0.17
- CRVS N/A
- Revenue
- HQI $32,610,000.00
- CRVS N/A
- Revenue This Year
- HQI N/A
- CRVS N/A
- Revenue Next Year
- HQI $1.38
- CRVS N/A
- P/E Ratio
- HQI $55.74
- CRVS N/A
- Revenue Growth
- HQI N/A
- CRVS N/A
- 52 Week Low
- HQI $8.94
- CRVS $2.54
- 52 Week High
- HQI $15.75
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- HQI 51.29
- CRVS 59.43
- Support Level
- HQI $9.30
- CRVS $5.90
- Resistance Level
- HQI $10.30
- CRVS $6.09
- Average True Range (ATR)
- HQI 0.35
- CRVS 0.33
- MACD
- HQI 0.04
- CRVS -0.02
- Stochastic Oscillator
- HQI 58.00
- CRVS 58.82
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).